The p73 is a tumor suppressor and belongs to the p53 family of proteins.
Introduction
Pancreatic cancer is one of the deadliest diseases and the 5 th leading cause of cancer-related deaths worldwide [1] . In Europe, the death rates from pancreatic cancer continue to increase in both sexes, and the median survival rate for patients diagnosed with metastatic disease is only 4.6 months [2] . At present, pancreatic cancer is the 4 th leading cause of death in Europe and is predicted to be the 2 nd cause of cancer-related deaths in 2020 [3] .
To date, it is still one of the most challenging solid tumors to treat. Most of the patients die within 1 year after diagnosis and only about 3-5% survive up to 5 years in the USA. This is due to the late onset of the disease, high incidence of metastasis and the lack of the effective treatment [4] .
Treatment of pancreatic cancer is difficult and depends on the stage of the disease at the time of diagnosis. The response to the currently available chemotherapeutics is disappointing and the poor outcome is likely stemming from a complex set of several factors described below.
In cases not suitable for the resection with curative intent, palliative chemotherapy may be used to improve the quality of life. Gemcitabine (GEM) was approved by the Food and Drug administration in 1998 for the treatment of patients with advanced pancreatic cancer. GEM remains the main first-line therapy for pancreatic patients regardless of the occurrence of primary and acquired resistance.
The resistance is partially due to DNA-repair polymorphism [5] , mutations in p53 pathway [6] or the existence of cancer stem cells [7] . Recently, combination treatments regiments with 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) brought some promise to overcome the resistance in patients suffering from metastatic disease, however, pancreatic cancer remains a major medical unmet need [8] .
Thus, there is an urgent need to develop more effective treatments for this type of cancer.
Pancreatic cancer is one of the cancer types in which mutant p53 impacts disease progression. TP53 is mutated in 75% cases of pancreatic carcinomas [9] .
TP53 gene mutations co-exist with activating mutations in classical oncogenes including K-Ras, which accounts for 45% of all pancreatic cancer cases [10] .
TP53 mutations are common across various tumor types and result with the loss of p53 tumor suppressor function and preferentially promote the so-called gain of new functions. As evidenced, mutant p53 is the main driver of disease progression in pancreatic cancers and selective therapies aiming at restoring p53 pathway to overcome p53 loss in cancer cells but not in normal cells, appear to be an attractive strategy for such diseases as chemotherapy-resistant pancreatic cancer. Despite the on going efforts, small molecules re-activating mutant p53 are still in clinical development [11] .
It has been previously shown that photodynamic therapy of cancer (PDT), that uses photoinducible compounds and light, is effective against numerous pancreatic cancer cell lines alone [12] or in combination with gemcitabine [13] .
The majority of the compounds that are applied in clinics in PDT are porphyrins and their derivatives [14] . Protoporphryin IX (PpIX) is a metabolite of γ aminolevulinic acid (ALA), a pro-drug applied in photodynamic therapy of cancer [14] . Protoporphyrin IX, itself, without light excitation, was shown to induce wild-type p53-related cell death in several human cancer cell lines including human colon carcinoma [15] . Next, it has recently been demonstrated that PpIX stabilizes and activates TAp73 and induces TAp73-dependent apoptosis in cancer cells lacking TP53 [16] .
Thioredoxin reductase 1 (TrxR1) is a component of Thioredoxin system responsible for maintaining redox homeostasis in cells [17] . TrxR has a protective role against cancer in normal cells, however, can contribute to tumor progression once the disease has already developed. Thus, TXNRD1 is often overexpressed in cancers and is a promising target for improved cancer therapy [17] .
Here, we found that protoporphyrin IX and benzoporphyrin derivative (BPD; verteporfin®) induce TAp73 and its pro-apoptotic targets on mRNA and protein levels. Next, it was demonstrated that PpIX and BPD induce reactive oxygen species (ROS) and antioxidant response genes HMOX-1 and NQO1. PpIX and BPD inhibited TrxR1 in vitro and in pancreatic cancer cells harboring mutant p53. Taken together, our data adds up to the mechanism by which PpIX and now BPD induce apoptosis in cancer cells harboring TP53 gene mutations, which is via reactivation of TAp73 tumor suppressor and inhibition of TrxR1.
Results

Protoporphyrin IX and benzoporphyrin derivative localize to cytoplasm of
Panc1 cancer cells.
Pancreatic ductal adenocarcinomas (PDAC) are cancers of poor clinical outcome due to chemoresistance and disease relapse and mutant p53 drives disease aggressiveness.
Whether the re-activation of TAp73 can compensate for the p53 loss in cancers with TP53 gain of function mutations has not been unequivocally demonstrated yet. For this reason, we tested the outcome of TAp73 activation in PDAC cancer cell lines harboring hot-spot TP53R273H .
6 First, we have assessed cellular localization of BPD in Panc1 cells ( Fig. 1a ).
Fluorescence microscopy indicated that BPD is uptaken to high degree by cancer cells. Next, we found that verteporfin localized in large in cytoplasm and partially in endoplasmic reticulum.
PpIX and BPD inhibit proliferation of PDAC cells but not of non-transformed human ductal epithelial cells.
To assess the impact of PpIX and BPD on the proliferation of PDAC cells we performed MTT proliferation assay. Standard treatments for advanced disease include monotherapy with gemcitabine (GEM) and we used it for comparative purpose.
MTT assay showed that PpIX and BPD inhibit cancer cells' proliferation ( Fig. 1b-e ).
In agreement with previous data, cancer cells expressing wild-type (wt) p53 (PaCa3) were sensitive to 72h-treatment with PpIX [15] ( Fig. 1b ) and showed enhanced growth inhibition upon BPD exposure. Interestingly, mutant p53-harboring cells (Panc1) were more sensitive to PpIX than PaCa3 cells and slightly less sensitive to BPD (Fig. 1c ).
The calculated IC 50 was 4.4 µM for PaCa3 (wtp53) cells and 3.5 µM Panc1 (mtp53R273H) cancer cells for PpIX and 2.2 and 2.8 µM for BPD, respectively.
Of note, murine pancreatic cancer cells Panc02 and human MiaPaCa2, were less sensitive to PpIX and BPD at the range of the concentrations tested ( Fig. 1d and data not shown) and normal human epithelial ductal cells were insensitive ( Fig. 1e ). On other hand, all cell lines were highly susceptible to low dose (25 µM) cisplatin and 5 µM gemcitabine.
Consistent with previous data wtp53 cancer cells were sensitive to PpIX [15] . Next, mutant p53 Panc1 cell line was the most sensitive among the cells tested. Based on the above and the previous studies, we selected Panc1 cell line and 2.5µg/ml compounds' concentration for further studies on cell death induction upon reactivation of TAp73.
PpIX and BPD induce apoptosis in PDAC cells
To investigate if growth inhibition observed in MTT assay is a consequence of the apoptosis, we have treated PaCa3 and Panc1 cells with 2.5 µg/ml PpIX or BPD for 48 h and performed propidium iodide and Annexin V stainings. We found that at the time-point tested, Panc1 undergo high late apoptosis after PpIX treatment as demonstrated by above 40% increase of PI positive cells. At this time-point, Annexin V positivity, indicating early apoptosis, increased by 12% or 9% after PpIX or BPD treatments ( Fig. 2c,d ). In PaCa3 cells, harboring wtp53, we observed 10% and 17% increase in PI positive cells after PpIX or BPD treatment respectively. The increase in Annexin V-positive cells was 5% for PpIX and 11% for BPD. Thus, both compounds induce early and late apoptosis in cancer cell lines tested.
PpIX and BPD induce TAp73 and its pro-apoptotic targets
It has been demonstrated that PpIX reactivates TAp73 tumor suppressor and induces TAp73-dependent apoptosis in TP53-null cancer cells [16] . To assess if the growth inhibition of PDAC by PpIX and BPD is a result of apoptosis, we evaluated the expression of TAp73 and its pro-apoptotic targets in two pancreatic cancer cells lines.
Western blotting results showed that in dark, both PpIX and BPD induce TAp73 levels, which correlates with the accumulation of its proapoptotic Bcl-2 protein family members (PUMA, Bax, and Bid) ( Fig. 3a,b ,c) and cleaved PARP. In Panc1 cells PpIX and PBD upregulate the expression of Bax, Bid, puma, noxa (Fig. 3d ). This indicates that cell apoptosis is due to activation of TAp73. Interestingly, we detected activation antioxidant response proteins, HO-1, and NF-E2-related transcription factor (Nrf2) ( Fig. 3a,b,c,d ). PpIX and BPD did not induce PARP cleavage, TAp73 and its proapoptotic targets at the effective concentrations ( Fig. 3e ).
PpIX and BPD induce reactive oxygen species in PDAC.
We observed accumulation of antioxidant response proteins by PpIX and BPD in PDAC cells; we thus sought to investigate if PpIX and BPD trigger accumulation of reactive oxygen species. We assessed the levels of ROS using DCFDA and HE probes. Fig. 4a ,b,c shows that PpIX and BPD induce ROS in PaCa3 and Panc1 cancer cells. Pre-treatment with ROS scavenger, resveratrol inhibited accumulation of ROS by PpIX and BPD in Panc1 cells (Suppl. Fig. 1a ). Importantly, the compounds did not induce ROS in HPDE cells (Suppl. Fig. 1b ).
PpIX and BPD are inhibitors of thioredoxin reductase
Protoporphyrin IX was first identified as an inhibitor of thioredoxin reductase in the in vitro screen [18] . Since we observed significant induction of ROS in cells treated with PpIX or BPD we reasoned that apart from active apoptosis, inhibition of TrxR might contribute to elevation of ROS in cancer cells.
As demonstrated in Fig. 5a , recombinant TrxR was inhibited by BPD. To assess if PpIX and BPD inhibit TrxR activity in cells, we treated Panc1 with PpIX or BPD for 6 h and assayed the activity using end-point Trx-dependent insulin reduction assay.
PpIX and BPD treatment inhibited TrxR1 in Panc1 cells ( Fig. 5b ) and in other mutant p53 harboring cell line, MiaPaCa2. Taken together, these data demonstrates that BPD is a potent inhibitor of TrxR in pancreatic cancer cells.
Discussion
Several protein kinases inhibitors were reported to have off-target effects. In example, BRAF inhibitor, vemurafenib used for metastatic melanoma [19] with good clinical outcome in some cases [20] , was manifested to induce unusual photosensitivity in patients [21] . The recent study by Klaeger et al. [22] demonstrates that several clinically applied kinase inhibitors including vemurafenib, in addition to their designed targets effectively inhibit ferrochelatase, the last enzyme in heme biosynthesis. The authors speculated that accumulation of protoporphyrin IX may lead to photosensitivity of the patients upon treatment with kinase inhibitors.
Next, PpIX is a metabolite of γ -aminolevulinic acid (ALA), heme precursor, a drug applied in photodynamic therapy of cancer [14] .
We have shown in a drug-repurposing approach that PpIX re-activates wild-type p53 and TAp73 and induces apoptosis in cancer cells. The mechanism is via inhibition of p53/MDM2 and TAp73/MDM2(X) interactions [15, 16] . Next, PpIX was identified in the in vitro screen as a potent, competitive inhibitor of thioredoxin reductase [18] .
Thus, here we speculated that PpIX exogenously delivered to pancreatic cancer cells induces apoptosis via activation of p53 protein family members and inhibition of TrxR.
The detailed analysis revealed that PpIX and its clinically applied analog, BPD also known under commercial name verteporfin®, inhibit proliferation of pancreatic cancer cells without affecting non-transformed cells. The mechanism of growth inhibition was by induction of apoptosis. Next, both compounds triggered antioxidant response and induced accumulation of reactive oxygen species only in cancer cells but not in normal HPDE cells. The above, prompted us to investigate if robust induction of ROS is a consequence of inhibition of TrxR. According to our findings, Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, GEM) (Abcam, UK) was prepared as 1 mM stock solution in 100% DMSO.
Verteporin uptake and cellular localization
Cells were incubated with 2.5 μ g/ml of BPD in cell media for 3h, washed three times with PBS and co-stained with ER-tracker Green for live-cell imaging (Molecular probes) or DAPI (Molecular Probes) according to manufacturer protocol. BPD was excited with 420 nm. The images were taken using Olympus IX-71 microscope and DeltaVision SoftWoRx.
Cell viability
Cell viability was assessed by MTT assay as provided by the manufacturer (Sigma-Aldrich, Germany) and as described previously [15] . Briefly, 3000 cells were seeded in 96-well plate and allowed to adhere overnight. The cells were treated with compounds for 72 h and the viability was measured using MTT reagent.
Real-time PCR
Quantitative PCR was performed as described previously [31] . Cells were seeded at 6-well plates, allowed to adhere and treated with 2.5 μ g/ml PpIX or BPD. mRNA after isolation was reverse transcribed to cDNA according to the manufacturer's instructions (Bio-Rad, Sundbyberg, Sweden). For qPCR reaction 150 nM; 10 ng cDNA; 7.5 μ l 2 × master mix (Bio-Rad) and water to a total of 15 μ l were used. 
Thioredoxin reductase activity assay
For the enzymatic activity of purified TrxR we followed the protocol previously described [24, 32] . Briefly, 10 nM of purified TrxR1[33] was pre-incubated with BPD 
Cell death detection
Propidum idodie and FITC-Annexin V (from BD Biosciences, San Jose, CA, USA)
staining was performed according to the manufacturer's protocols and FACS analysis was performed with the CELLQuest software (CELLQuest, Franklin Lakes, NJ, USA) as described previously [34] .
ROS measurement
Reactive oxygen species were detected using 2',7'-dichlorofluorescein (H 2 DCF) (Sigma-Aldrich, Germany) and method described previously [24] .
Hydroethidine staining was performed according to the manufacturer protocol (Life Technologies, Sweden). Data analysis was performed with the CELLQuest software (CELLQuest, Franklin Lakes, NJ, USA).
Western blotting
Western blotting was performed according to the standard protocol. Briefly, 100 μ g of total cell lysate was subjected to electrophoresis, after transfer the following antibodies were used to detect proteins: anti-TAp73 (Bethyl Laboratories, TX, USA), 
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